Roles ofN-Glycans with α2,6 as well as α2,3 Linked Sialic Acid in Infection by Polyoma Virus  by Chen, Minhao Howard & Benjamin, Thomas
VIROLOGY 233, 440–442 (1997)
ARTICLE NO. VY978596
SHORT COMMUNICATION
Roles of N-Glycans with a2,6 as well as a2,3 Linked Sialic Acid in Infection by Polyoma Virus
Minhao Howard Chen and Thomas Benjamin1
Department of Pathology, Harvard Medical School Boston, Massachusetts 02115
Received September 24, 1996; returned to author for revision November 19, 1996; accepted May 5, 1997
Specific glycosylation inhibitors were used to show that N-glycans, and not O-glycans or glycolipids, constitute the major
class of receptors on 3T3 cells for polyoma virus. Sialic acid (SA)-specific lectins were used in attempts to confirm the
expected SA linkage on N-linked glycans. A lectin specific for a2,6 linked SA, a non-receptor type, was slightly more effective
in blocking infection than a lectin specific for a2,3 linked SA which corresponds to the known receptor specificity. Possible
explanations are suggested for this unexpected result. q 1997 Academic Press
Cell surface oligosaccharides containing sialic acid tion with specific inhibitors of glycosylation. Two inhibi-
tors of N-glycosylation were used: tunicamycin, which(5 N-acethylneuraminic acid; NeuAc or SA) are critical
determinants of the receptor(s) for polyoma virus. Earlier blocks an early step in the N-glycosylation pathway in-
volving transfer between UDP-GlcNAc and dolichol-1-work by Paulson and colleagues has shown that the
oligosaccharide sequence NeuAca2,3 Galb1,3GalNAc is phosphate (9), and 1-deoxymannojirimycin, which blocks
a-mannosidase I, essential for trimming N-linked poly-recognized by both large and small plaque strains of
polyoma as an essential component of the receptor. In mannose chains for further glycosylation (10). Benzyl-a-
N-acetylgalactosamine (BenzylGalNAc) was used as aaddition, they showed that small but not large plaque
strains can recognize a branched disialyl oligosaccha- competitive inhibitor of chain elongation of O-linked car-
bohydrates (11). Cells pretreated with inhibitor were in-ride of the sequence NeuAca2,3 Galb 1,3 (Neu Aca2,6)
GalNAc and that neither strain recognizes straight chains fected with either PTA, a large plaque strain, or RA, a
small plaque strain. The virus inoculum was removedwith terminal a2,6-linked SA (1–3). Recent studies by X-
ray crystallography have defined specific contacts be- and the infected cells incubated for 40 hr in the absence
of inhibitors. The percentages of cells infected were de-tween model sialyloligosaccharides and amino acids in
VP1, the major viral capsid protein (4, 5). These studies termined by immunofluorescent staining for nuclear T
also confirmed the specificities defined earlier for the SA antigen (Fig. 1).
linkages recognized by large and small plaque viruses. A Pretreatment with either tunicamycin or 1-deoxyman-
single site polymorphism in VP1 constitutes the essential nojirimycin inhibited virus infection by 90% or greater.
difference between large and small plaque strains (6). In contrast, BenzylGalNAc had virtually no effect on the
This polymorphism underlies the striking differences in susceptibility of the cells to infection. These results es-
pathogenicity between the two virus subgroups (7, 8), as tablish that the major class of polyoma receptors on 3T3
well as the differences in their abilities to recognize and cells are N-linked glycans and rule out significant roles
discriminate between branched and straight chain SAs. of either O-linked sugars or glycolipids. Results were
While the importance of polyoma VP1–SA interactions qualitatively the same for large and small plaque viruses,
has long been recognized, the full nature of virus recep- although inhibition by the N-glycosylation inhibitors was
tor(s) and mode of entry remains unknown. Specifically, consistently greater for the large plaque than for the
it has not been shown whether receptors are sialoglyco- small plaque strain. This difference may be related to
proteins with N- or O-linked sugar chains or possibly the broader specificity and greater diversity of receptors
sialoglycolipids or whether they represent a distinct or for small plaque viruses (3).
multiple species within these classes. As a first step in Tunicamycin-treated cells which became resistant to
characterizing SA-containing conjugates that function as polyoma infection showed no loss of viability based on
polyoma receptors, 3T3 cells were treated prior to infec- trypan blue exclusion, indicating that inhibition was not
due to general toxicity of the drug. In another papova
virus system, exposure of cells to similar levels of tuni-1 To whom reprint requests should be addressed.
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infection. Results were substantially the same for both
virus types, although SNA, which targets the nonreceptor
linkage, was consistently more inhibitory than MALII. A
third lectin, from lentil, with specificity for high mannose
cores, was ineffective in blocking infection by either virus.
SA-specific lectins inhibited infection by 40–60% com-
pared to untreated controls. Higher concentrations of lec-
tin could not be used because of cellular toxicity. The
fact that inhibition by both lectins was incomplete can
be explained by any one or a combination of a number of
different factors, including the high density of SA-binding
sites on the virus surface allowing virus to compete effec-
tively with lectins, the relatively high multiplicity of virus
used, the likely turnover of receptor molecules, and the
possibility that multiple glycoprotein species with differ-
ent reactivities toward the lectins may be involved.
The unexpected finding of inhibition of polyoma virus
infection by the SNA lectin with specificity toward what
FIG. 1. The effect of N- and O-linked glycosylation inhibitors on
has clearly been shown to be a nonreceptor SA linkageinfection of 3T3 cells by small and large plaque polyomavirus strains.
raises a number of interesting questions. One possibility3T3 cells seeded onto coverslips at roughly 80% confluence were
treated with the N-glycosylation inhibitors, tunicamycin (2 mg/ml for 4 hr) is that a class of receptors contains bi- (or multi-) anten-
or 1-deoxymannojirimycin (0.4 mM for 18 hr), or with the O-glycosylation nary carbohydrate chains with both a2,3 and a2,6 link-
inhibitor BenzylGalNAc (10 mM for 72 hr). Treated cells were then ages to SA and that lectin binding to either type of chain
infected with virus of either the small plaque strain RA or the large
somehow prevents the virus from binding or being inter-plaque strain PTA (m.o.i. of 2– 5 PFU/cell) in the presence of the same
nalized. Another possibility deserving of investigation isinhibitor at 377 for 1.5 hr. Unbound virus was removed by washing
three times with PBS containing inhibitor. Infected cells were incubated that this lectin blocks infection by binding not to the cell
for 40 hr in standard growth medium without inhibitor. Coverslips were but to the virus. As the outer capsid protein of a virus
then washed with PBS and fixed in cold 100% methanol for 5 min. Fixed which replicates and assembles in the nucleus, VP1 is
cells were washed three times with 3% calf serum in PBS (buffer A) and
not expected to be N-glycosylated. However, a numberprocessed for immunofluorescent staining of polyomavirus T antigens.
of isoelectric subspecies of VP1 exist, not all of whichCoverslips were incubated with a 1:200 dilution of rat polyclonal anti-
T antibodies in buffer A for 30 min and then with a 1:200 dilution of
fluorescein goat anti-rat IgG for 20 min. A total of approximately 1000
cells were scored for nuclear T antigen by immunofluorescent micros-
copy.
camycin for even longer periods was also found to be
nontoxic and even resulted in enhancement of virus sus-
ceptibility (12).
A surprising result was obtained in inhibition studies
using lectins specific for different SA linkages on N-gly-
cans. The lectin MAL II from Maachia amurensis is spe-
cific for a2,3-linked SA (13) and was chosen to block the
known ‘‘receptor type’’ of linkage. The SNA lectin from
Sambucca nigra with specificity for a2,6-linked SA (14),
i.e., the ‘‘nonreceptor’’ type of linkage, was chosen as a
negative control. Both lectins are known to recognize N-
linked carbohydrates with terminal unbranched SAs of
the appropriate linkage, and neither is known to bind to FIG. 2. The effect of SA-specific lectins on virus infection. 3T3 cells
branched disialyl structures found predominantly on O- prepared as in Fig. 1 were treated with either M. amurensis II (MAL-
II) lectin or S. nigra (SNA) lectin (100 mg/300 ml) for 1 hr prior to infection.linked chains (15, 16). 3T3 cells were incubated with
Cells were then infected with small plaque RA or large plaque PTAthese lectins for 1 hr prior to infection and then infected
virus in the presence of lectin for 1.5 hr. Unbound virus and lectin werein the continued presence of lectin. Virus and lectin were
removed by washing three times with PBS and the infected cells were
removed and the cells were incubated for 40 hr in the incubated in standard growth medium without lectin for 40 hr. Cells
absence of lectin before being stained for T antigen (Fig. were subjected to T antigen immunofluorescent staining and quantified
as described in the legend to Fig. 1.2). Surprisingly, both lectins were effective in blocking
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